Steven Mah
Stock Analyst at TD Cowen
(2.11)
# 2,648
Out of 4,814 analysts
31
Total ratings
31.03%
Success rate
8.81%
Average return
Main Sectors:
Stocks Rated by Steven Mah
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TWST Twist Bioscience | Reiterates: Buy | $58 | $39.50 | +46.84% | 3 | Nov 26, 2024 | |
| BLFS BioLife Solutions | Maintains: Buy | $28 → $31 | $21.79 | +42.27% | 2 | Nov 13, 2024 | |
| DNA Ginkgo Bioworks Holdings | Maintains: Outperform | $280 → $120 | $7.85 | +1,429.64% | 2 | Mar 1, 2024 | |
| RXRX Recursion Pharmaceuticals | Initiates: Market Perform | n/a | $5.50 | - | 1 | Jan 26, 2024 | |
| SDGR Schrödinger | Initiates: Outperform | $42 | $25.21 | +66.60% | 1 | Jan 26, 2024 | |
| ABCL AbCellera Biologics | Initiates: Outperform | n/a | $2.42 | - | 1 | Feb 28, 2023 | |
| OABI OmniAb | Initiates: Outperform | $10 | $1.80 | +455.56% | 1 | Feb 22, 2023 | |
| ABSI Absci | Upgrades: Outperform | n/a | $3.10 | - | 1 | Aug 12, 2022 | |
| CDXS Codexis | Maintains: Outperform | $39 → $21 | $2.12 | +890.57% | 2 | Jul 15, 2022 | |
| NTRA Natera | Maintains: Overweight | $150 → $155 | $148.08 | +4.67% | 4 | Jul 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $1.10 | +2,445.45% | 1 | May 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $135 → $140 | $17.86 | +684.09% | 3 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $20 → $52 | $1.17 | +4,344.44% | 3 | Feb 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $340 → $415 | $71.16 | +483.19% | 4 | Dec 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $40 → $80 | $2.84 | +2,716.90% | 1 | Dec 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $168 → $250 | $25.15 | +894.04% | 1 | Jul 8, 2020 |
Twist Bioscience
Nov 26, 2024
Reiterates: Buy
Price Target: $58
Current: $39.50
Upside: +46.84%
BioLife Solutions
Nov 13, 2024
Maintains: Buy
Price Target: $28 → $31
Current: $21.79
Upside: +42.27%
Ginkgo Bioworks Holdings
Mar 1, 2024
Maintains: Outperform
Price Target: $280 → $120
Current: $7.85
Upside: +1,429.64%
Recursion Pharmaceuticals
Jan 26, 2024
Initiates: Market Perform
Price Target: n/a
Current: $5.50
Upside: -
Schrödinger
Jan 26, 2024
Initiates: Outperform
Price Target: $42
Current: $25.21
Upside: +66.60%
AbCellera Biologics
Feb 28, 2023
Initiates: Outperform
Price Target: n/a
Current: $2.42
Upside: -
OmniAb
Feb 22, 2023
Initiates: Outperform
Price Target: $10
Current: $1.80
Upside: +455.56%
Absci
Aug 12, 2022
Upgrades: Outperform
Price Target: n/a
Current: $3.10
Upside: -
Codexis
Jul 15, 2022
Maintains: Outperform
Price Target: $39 → $21
Current: $2.12
Upside: +890.57%
Natera
Jul 6, 2021
Maintains: Overweight
Price Target: $150 → $155
Current: $148.08
Upside: +4.67%
May 11, 2021
Initiates: Overweight
Price Target: $28
Current: $1.10
Upside: +2,445.45%
Mar 5, 2021
Maintains: Overweight
Price Target: $135 → $140
Current: $17.86
Upside: +684.09%
Feb 11, 2021
Upgrades: Overweight
Price Target: $20 → $52
Current: $1.17
Upside: +4,344.44%
Dec 22, 2020
Upgrades: Overweight
Price Target: $340 → $415
Current: $71.16
Upside: +483.19%
Dec 16, 2020
Upgrades: Overweight
Price Target: $40 → $80
Current: $2.84
Upside: +2,716.90%
Jul 8, 2020
Maintains: Overweight
Price Target: $168 → $250
Current: $25.15
Upside: +894.04%